Drug · CHEMBL888

GEMCITABINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. GEMCITABINE. Drugs and targets, record CHEMBL888. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL888

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: GEMCITABINE; ChEMBL
ChEMBL ID: CHEMBL888; ChEMBL
Type: Small molecule; ChEMBL
Brand names: Gemzar; ChEMBL
Other names: Gemcitabina, LY-188011, LY188011, NSC-613327; ChEMBL
Other form: GEMCITABINE HYDROCHLORIDE, CHEMBL1637; Drugs and targets
DrugBank: DB00441; DrugBank
InChIKey: SDUQYLNIPVEERB-QPPQHZFASA-N; ChEMBL
Open Targets' highest stage: Approval, for 2 of its 199 diseases, from ATC and TTD; Open Targets

Targets14

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
POLA1	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5422
POLA2	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/23649
POLD1	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5424
POLD2	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5425
POLD3	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/10714
POLD4	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/57804
POLE	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5426
POLE2	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5427
POLE3	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/54107
PRIM1	DNA polymerase (alpha/delta/epsilon)	DNA polymerase (alpha/delta/epsilon) inhibitor	INHIBITOR	https://conductscience.org/library/genes/5557

1 to 10 of 14Source ChEMBL

See all 14 targets

Diseases199

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
malignant pancreatic neoplasm	Phase 3	ClinicalTrials.gov	305	304	https://conductscience.org/library/drugs?q=MONDO_0009831
pancreatic neoplasm	Phase 3	ClinicalTrials.gov	299	298	https://conductscience.org/library/drugs?q=MONDO_0021040
non-small cell lung carcinoma	Approval	TTD	295	293	https://conductscience.org/library/drugs?q=MONDO_0005233
pancreatic adenocarcinoma	Phase 3	ClinicalTrials.gov	243	243	https://conductscience.org/library/drugs?q=MONDO_0006047
exocrine pancreatic carcinoma	Phase 3	ClinicalTrials.gov	237	237	https://conductscience.org/library/drugs?q=MONDO_0005192
breast cancer	Phase 3	ClinicalTrials.gov	139	139	https://conductscience.org/library/drugs?q=MONDO_0007254
pancreatic ductal adenocarcinoma	Phase 3	ClinicalTrials.gov	136	136	https://conductscience.org/library/drugs?q=MONDO_0005184
biliary tract cancer	Phase 3	ClinicalTrials.gov	114	114	https://conductscience.org/library/drugs?q=MONDO_0003060
nasopharyngeal carcinoma	Phase 3	ClinicalTrials.gov	106	106	https://conductscience.org/library/drugs?q=MONDO_0015459
intrahepatic cholangiocarcinoma	Phase 3	ClinicalTrials.gov	74	74	https://conductscience.org/library/drugs?q=MONDO_0003210

1 to 10 of 199Source Open Targets

See all 199 diseases

Trials2,544

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 19 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00093795	Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer	Phase 3	4,894	2017-12-12	gemcitabine	Its name	ClinicalTrials.gov
NCT00011986	Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer	Phase 3	4,312	2016-04-19	gemcitabine	Its name	ClinicalTrials.gov
NCT03036098	Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer	Phase 3	1,314	2025-09-18	gemcitabine	Its name	ClinicalTrials.gov
NCT02576574	Avelumab in First-line NSCLC (JAVELIN Lung 100)	Phase 3	1,214	2023-01-04	gemcitabine	Its name	ClinicalTrials.gov
NCT02807636	Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma	Phase 3	1,213	2023-12-13	gemcitabine	Its name	ClinicalTrials.gov
NCT03164616	Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).	Phase 3	1,186	2022-04-07	gemcitabine	Its name	ClinicalTrials.gov
NCT02993731	A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma	Phase 3	1,134	2021-06-10	gemcitabine	Its name	ClinicalTrials.gov
NCT00981058	First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin	Phase 3	1,093	2016-06-27	gemcitabine	Its name	ClinicalTrials.gov
NCT04003636	Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)	Phase 3	1,069	2023-12-22	gemcitabine	Its name	ClinicalTrials.gov
NCT03732677	Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC	Phase 3	1,063	2025-07-03	gemcitabine	Its name	ClinicalTrials.gov

1 to 10 of 2,544

See all 2,544 trials

Comparisons in its trials392

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): Number of Patients With Adverse Events	560 of 561	543 of 547	1,108	NCT02993731	Trial comparisons
Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): deaths from any cause	419 of 561	400 of 547	1,108	NCT02993731	Trial comparisons
Napabucasin Plus Nab-paclitaxel With Gemcitabine (Safety Population) vs Nab-paclitaxel With Gemcitabine (Safety Population): serious adverse events	330 of 561	273 of 547	1,108	NCT02993731	Trial comparisons
Necitumumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause	476 of 538	487 of 541	1,079	NCT00981058	Trial comparisons
Necitumumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: serious adverse events	262 of 538	208 of 541	1,079	NCT00981058	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: Proportion of Patients Who Undergo Cystectomy	469 of 533	441 of 530	1,063	NCT03732677	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: Pathologic Complete Response (pCR) Rates at Time of Cystectomy	199 of 533	146 of 530	1,063	NCT03732677	Trial comparisons
Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)	138 of 529	122 of 534	1,063	NCT04003636	Trial comparisons
Arm A (Pembrolizumab+Gemcitabine+Cisplatin) vs Arm B (Placebo+Gemcitabine+Cisplatin): Number of Participants Who Experience One or More Adverse Events (AE)	524 of 529	532 of 534	1,063	NCT04003636	Trial comparisons
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause	27 of 533	29 of 526	1,059	NCT03732677	Trial comparisons

1 to 10 of 392

See all 392 comparisons in its trials

Papers from its trials1,202

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41405563	RESULT	1	PubMed
40713827	RESULT	1	PubMed
40542585	RESULT	1	PubMed
40382318	RESULT	1	PubMed
40131728	RESULT	1	PubMed
40068595	RESULT	1	PubMed
39822559	RESULT	1	PubMed
39288781	RESULT	1	PubMed
38964333	RESULT	1	PubMed
38849479	RESULT	1	PubMed

1 to 10 of 1,202

See all 1,202 papers from its trials

Tests in its trials8

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	Source
Arithmetic Fluency Task	1	ConductCognition
Continuous Performance Test	1	ConductCognition
Digit Span Test	1	ConductCognition
Hidden Path Learning	1	ConductCognition
1-Back Task	1	ConductCognition
Paired Associate Learning	1	ConductCognition
Symbol Scan Task	1	ConductCognition
Verbal Learning	1	ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL888

GET https://conductscience.org/api/drugs/v1/CHEMBL888/diseases?page=2

API reference For AI assistants